{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2023"],"data_sharing_plan":["IPD Sharing (as of October 2023): No\nDescription: At this time, IPD sharing has not been defined and/or decided if it will be shared."],"condition":["Kidney Neoplasms","Gynecologic Cancer","Pancreas Cancer","Skin Cancer","Solid Tumor","Colorectal Cancer","Head and Neck Cancer","Non Small Cell Lung Cancer","Pancreatic Neoplasms","Kidney Cancer","Cancer"],"disease":["Gynecologic Cancer","Kidney Neoplasms","Pancreas Cancer","Skin Cancer","Solid Tumor","Colorectal Cancer","Non Small Cell Lung Cancer","Head And Neck Cancer","Kidney Cancer","Pancreatic Neoplasms","Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/6564"],"location":["United States"],"study_start_month":["4"],"keyword":["Immune Checkpoint Inhibitors","Capecitabine","Cytokine","DEKA","DK210(EGFR)","Oncology","IL-2","Immuno-oncology","IL-10","Pembrolizumab","Oxaliplatin","Interleukin 2","Nivolumab","Immunotherapy","Paclitaxel","Interleukin 10","Carboplatin","DEKA Biosciences","Fluorouracil"],"repository":["ECRIN MDR"],"study_status":["Recruiting"],"additional_accession":[]},"is_claimable":false,"name":"Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors","description":"This study will evaluate safety, pharmacodynamics and biomarkers of subcutaneous (SC) DK210(EGFR) given as monotherapy and in combination with immunotherapy, chemotherapy or radiation.","dates":{"creation":"2023-04-15"},"accession":"6564","cross_references":{"ClinicalTrials___gov":["NCT05704985"]}}